Our Beginning May 1991 Myriad Genetics, Inc. is founded, making it one of the first genomics companies in history. 1991
First Gene Discovery Fall 1993 Myriad announces the discovery of the P16 gene that is associated with hereditary melanoma. 1993
BRCA1 Discovery September 1994 Myriad scientists publish in Science the discovery of the BRCA1 gene that is associated with hereditary breast and ovarian cancer. 1994
Public Company October 1995 Myriad becomes a public company and is traded on NASDAQ under the ticker: MYGN. 1995
BRCA2 Discovery December 1995 Myriad announces the discovery of the BRCA2 gene that is associated with hereditary breast and ovarian cancer. 1995
BRACAnalysis® Launches November 1996 Myriad launches BRACAnalysis®, the first full length gene sequencing test for a major, common disease, for the oncology market. 1996
PTEN Discovery March 1997 Myriad announces the discovery of the PTEN gene that is associated with a large number of cancers. 1997
ProNet Launches January 1998 Myriad launches ProNet, a proprietary protein-interaction technology. 1998
Myriad Pharmaceuticals April 1999 Myriad incorporates Myriad Pharmaceuticals to develop novel therapies. 1999
COLARIS® Launches September 2000 Myriad launches COLARIS®, a genetic test for hereditary colorectal and uterine cancer. 2000
MELARIS® Launches November 2001 Myriad launches MELARIS®, a test for melanoma. Myriad publishes in Cell, the discovery of a novel HIV cellular process. 2001
COLARIS AP® Launches May 2002 Myriad launches COLARIS AP®, a genetic test for FAP colon cancer syndrome. 2002
DEP1 Discovery February 2003 Myriad announces the discovery of major depression gene DEP1 in collaboration with Abbott Laboratories. 2003
Myriad submits investigational new drug applications June 2004 Myriad submits investigational new drug applications on two cancer drugs to FDA. 2004
Clinical Trial for Phase 2 Alzheimer's drug May 2005 Myriad announces results of a Phase 2 Alzheimer’s drug clinical trial. 2005
BART Launches August 2006 Myriad launches BART, a large rearrangement test for high-risk patients with breast cancer. 2006
Phase 2 clinical trial for Azixa August 2007 Myriad announces third Phase 2 clinical trial for Azixa, a molecular disruption agent. 2007
Preventative BRACAnalysis® Launches January 2008 Myriad launches BRACAnalysis® for the women’s health preventative care market, significantly expanding access to genetic cancer testing. 2008
Prolaris® Launches March 2010 Myriad launched Prolaris®, the first ever prognostic test to predict prostate cancer survival and help guide treatment decisions. 2010
PARP Companion Diagnostics 2011 Myriad enters into three companion diagnostic collaborations for PARP inhibitors used in patients with ovarian cancer. 2011
One-Million Milestone February 2013 The one-millionth patient is tested with BRACAnalysis® test. 2013
BRACAnalysis CDx® Receives FDA Approval December 2014 Myriad receives FDA approval for its BRACAnalysis CDx® test to identify patients with ovarian cancer who may benefit from the PARP inhibitor Lynparza™ (olaparib). 2014
Expansion into Mental Health August 2016 Myriad acquires Assurex Health and the GeneSight® genetic test for several mental health conditions. 2016
EndoPredict® Launches March 2017 EndoPredict® test is launched in the United States, providing three separate results to optimize treatment for patients with breast cancer. 2017
RiskScore® Launches September 2017 Myriad launches RiskScore® test, providing women with a comprehensive, personalized breast cancer risk assessment. 2017
BRACAnalysis CDx® Companion Diagnostic January 2018 Myriad receives FDA approval for BRACAnalysis CDx® as a companion diagnostic for Lynparza™ in patients with metastatic breast cancer. 2018
Expansion into Reproductive Health July 2018 Myriad acquires Counsyl and enters the reproductive genetic testing market. 2018
RiskScore® Validation in Additional Ancestries December 2018 Myriad validates first ever polygenic risk assessment to predict breast cancer risk in women of Hispanic ancestry. 2018
Paul Diaz Named CEO August 2020 Paul J. Diaz appointed president and chief executive officer of Myriad Genetics. 2020
Helping More Patients March 2021 Myriad Genetics joins forces with Intermountain Precision Genomics for a comprehensive offering of germline and somatic tumor testing services. 2021
Expanding Access to Genetic Testing August 2021 Myriad Genetics launches the first polygenic breast cancer risk assessment score (RiskScore®) validated for women of all ancestries. 2021
Launch of Precise™ Solutions March 2022 Myriad Genetics advances precision oncology with new Precise™ Solutions, combining genetic insights from multiple tests to guide treatment decisions and improve patient care. 2022